Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Alzheimer's Disease

Free Subscription Articles published in JAMA Retrieve available abstracts of 60 articles: HTML format

Single Articles

July 2026
1. LYNDON S, Behlke LM, Urizar JC, Daffner KR, et al
   Alzheimer Disease Biomarkers and Assisted Dying: When Diagnosis Becomes a Deadline.
   JAMA. 2026 Jul 9. doi: 10.1001/jama.2026.11317.
   PubMed    
   
   
   
2. RUBIN R
   First Alzheimer Disease Blood Test May Produce Many False-Positive Results, Study Finds.
   JAMA. 2026 Jul 2. doi: 10.1001/jama.2026.12326.
   PubMed    
   
   
   June 2026
3. HSIAO JK
   Stopping Alzheimer Disease: 50 Years of Progress.
   JAMA. 2026 Jun 22. doi: 10.1001/jama.2026.10969.
   PubMed    
   
   
   
4. CASALETTO KB, Dubal DB
   Female Clinical Resilience Despite Pathologic Risk in Alzheimer Disease.
   JAMA. 2026 Jun 10. doi: 10.1001/jama.2026.9351.
   PubMed    
   
   
   April 2026
5. KOSAKA M, Kami M
   Treatment of Early Symptomatic Alzheimer Disease With Valacyclovir.
   JAMA. 2026 Apr 2. doi: 10.1001/jama.2026.1102.
   PubMed    
   
   
   
6. DEVANAND DP, Wei R, Qian M
   Treatment of Early Symptomatic Alzheimer Disease With Valacyclovir-Reply.
   JAMA. 2026 Apr 2. doi: 10.1001/jama.2026.1105.
   PubMed    
   
   
   March 2026
7. RUBIN R
   Lithium for Alzheimer Disease-Pilot Study Sets the Stage for Larger Trials.
   JAMA. 2026 Mar 20. doi: 10.1001/jama.2026.3046.
   PubMed    
   
   
   
8. ANDERER S
   Alzheimer Disease Sex Differences May Be Tied to P-Tau217.
   JAMA. 2026 Mar 13. doi: 10.1001/jama.2026.1013.
   PubMed    
   
   
   January 2026
9. WHITSON HE, Fowler NR, Mielke MM
   Blood-Based Biomarkers for Alzheimer Disease: Preventing Unintended Consequences.
   JAMA. 2026 Jan 22. doi: 10.1001/jama.2025.26049.
   PubMed    
   
   
   December 2025
10. KNOPMAN DS
    Valacyclovir and Symptomatic Alzheimer Disease-No Evidence for Benefit.
    JAMA. 2025 Dec 17. doi: 10.1001/jama.2025.20795.
    PubMed    
    
    
    
11. 
    Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: Research Summary.
    JAMA. 2025 Dec 17:e2522830. doi: 10.1001/jama.2025.22830.
    PubMed    
    
    
    
12. DEVANAND DP, Wisniewski T, Razlighi Q, Qian M, et al
    Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial.
    JAMA. 2025 Dec 17:e2521738. doi: 10.1001/jama.2025.21738.
    PubMed     Abstract available
    
    
    
13. RUBIN R
    Alzheimer Disease Blood Test Cleared for Primary Care, but Questions Remain About Its Use.
    JAMA. 2025 Dec 5. doi: 10.1001/jama.2025.21573.
    PubMed    
    
    
    September 2025
14. ANDERER S
    Alzheimer Disease Exacerbated by Air Pollution, Study Suggests.
    JAMA. 2025 Sep 26. doi: 10.1001/jama.2025.13889.
    PubMed    
    
    
    
15. RUBIN R
    Trying to Unravel Why Alzheimer Disease Is More Common in Women.
    JAMA. 2025 Sep 26. doi: 10.1001/jama.2025.16269.
    PubMed    
    
    
    
16. ANDERER S
    First Antiamyloid Injectable Approved for Early Alzheimer Disease.
    JAMA. 2025 Sep 26. doi: 10.1001/jama.2025.13885.
    PubMed    
    
    
    August 2025
17. RUBIN R
    Treating Alzheimer Disease With Antiamyloid Therapies-The Real-World Experience Grows.
    JAMA. 2025 Aug 22. doi: 10.1001/jama.2025.14180.
    PubMed    
    
    
    
18. HUNT V
    An Alzheimer Biomarker Is Elevated in Newborns-Dementia Researchers Want to Know How They Clear It.
    JAMA. 2025 Aug 8. doi: 10.1001/jama.2025.13588.
    PubMed    
    
    
    July 2025
19. CHEN KY, Ross JS, Cohen AB, Karlawish J, et al
    Demographic Data Supporting FDA Authorization of AI Devices for Alzheimer Disease and Related Dementias.
    JAMA. 2025 Jul 30:e2512779. doi: 10.1001/jama.2025.12779.
    PubMed    
    
    
    June 2025
20. MOSCOSO A, Heeman F, Raghavan S, Costoya-Sanchez A, et al
    Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity.
    JAMA. 2025 Jun 16. doi: 10.1001/jama.2025.7817.
    PubMed     Abstract available
    
    
    
21. RUBIN R
    What to Know About the First FDA-Cleared Blood Test for Alzheimer Biomarkers.
    JAMA. 2025 Jun 13. doi: 10.1001/jama.2025.9013.
    PubMed    
    
    
    May 2025
22. ANDERER S
    Knowing Alzheimer Disease Risk May Reduce Lifestyle Change Motivation.
    JAMA. 2025 May 30. doi: 10.1001/jama.2025.7764.
    PubMed    
    
    
    January 2025
23. MINTZKER Y
    Blood Biomarkers to Detect Alzheimer Disease.
    JAMA. 2025 Jan 23. doi: 10.1001/jama.2024.25294.
    PubMed    
    
    
    
24. PALMQVIST S, Hansson O
    Blood Biomarkers to Detect Alzheimer Disease-Reply.
    JAMA. 2025 Jan 23. doi: 10.1001/jama.2024.25297.
    PubMed    
    
    
    September 2024
25. DEVERKA PA, Lin GA, Phillips KA
    Payer Coverage Considerations for Alzheimer Disease Blood-Based Biomarker Tests.
    JAMA. 2024 Sep 30. doi: 10.1001/jama.2024.19084.
    PubMed    
    
    
    August 2024
26. RUBIN R
    A Blood Test for Alzheimer Disease, Repurposing GLP-1s, and Wildfire Smoke-Highlights From the AAIC.
    JAMA. 2024 Aug 16. doi: 10.1001/jama.2024.13816.
    PubMed    
    
    
    July 2024
27. PALMQVIST S, Tideman P, Mattsson-Carlgren N, Schindler SE, et al
    Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.
    JAMA. 2024 Jul 28:e2413855. doi: 10.1001/jama.2024.13855.
    PubMed     Abstract available
    
    
    
28. SALLOWAY S, Rowe C, Burns JM
    Are Blood Tests for Alzheimer Disease Ready for Prime Time?
    JAMA. 2024 Jul 28. doi: 10.1001/jama.2024.12814.
    PubMed    
    
    
    
29. LU Y, Pike JR, Chen J, Walker KA, et al
    Changes in Alzheimer Disease Blood Biomarkers and Associations With Incident All-Cause Dementia.
    JAMA. 2024 Jul 28:e246619. doi: 10.1001/jama.2024.6619.
    PubMed     Abstract available
    
    
    
30. HARRIS E
    FDA Greenlights Second Alzheimer Drug, Donanemab.
    JAMA. 2024 Jul 26. doi: 10.1001/jama.2024.13386.
    PubMed    
    
    
    June 2024
31. RUBIN R
    A Neurologist Learned He Had Alzheimer Disease 8 Years Ago-Here's What He Wants People to Know.
    JAMA. 2024 Jun 28. doi: 10.1001/jama.2024.10805.
    PubMed    
    
    
    May 2024
32. HARRIS E
    Study: 2 APOE4 Copies May Indicate Genetic Form of Alzheimer Disease.
    JAMA. 2024 May 31. doi: 10.1001/jama.2024.9649.
    PubMed    
    
    
    
33. THAMBISETTY M, Howard R
    Conveying Risks of Harm in Alzheimer Disease by Amyloid Lowering.
    JAMA. 2024 May 6. doi: 10.1001/jama.2024.7548.
    PubMed    
    
    
    April 2024
34. RUBIN R
    Could GLP-1 Receptor Agonists like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?
    JAMA. 2024 Apr 19. doi: 10.1001/jama.2024.1017.
    PubMed    
    
    
    March 2024
35. KO D, Pascual-Leone A, Shah SJ
    Use of Lecanemab for Patients With Cardiovascular Disease: The Challenge of Uncertainty.
    JAMA. 2024 Mar 15. doi: 10.1001/jama.2024.2991.
    PubMed    
    
    
    
36. HARRIS E
    Biomarker Changes Can Begin 18 Years Before Alzheimer Disease Diagnosis.
    JAMA. 2024 Mar 6. doi: 10.1001/jama.2024.1568.
    PubMed    
    
    
    February 2024
37. HARRIS E
    Aducanumab Combined With Focused Brain Ultrasound More Effective.
    JAMA. 2024;331:466-467.
    PubMed    
    
    
    
38. HARRIS E
    Commercial Blood Test May Identify Alzheimer Disease Brain Pathology.
    JAMA. 2024 Feb 7. doi: 10.1001/jama.2024.0175.
    PubMed    
    
    
    December 2023
39. POMARA N, Imbimbo BP
    Use of Donanemab in Early Symptomatic Alzheimer Disease.
    JAMA. 2023;330:2304.
    PubMed    
    
    
    
40. EVANS CD, Sims JR
    Use of Donanemab in Early Symptomatic Alzheimer Disease-Reply.
    JAMA. 2023;330:2304-2305.
    PubMed    
    
    
    November 2023
41. RAFII MS, Fortea J
    Down Syndrome in a New Era for Alzheimer Disease.
    JAMA. 2023 Nov 22. doi: 10.1001/jama.2023.22924.
    PubMed    
    
    
    September 2023
42. RUBIN R
    Who Should-and Can-Get Lecanemab, the New Alzheimer Disease Drug?
    JAMA. 2023 Sep 27. doi: 10.1001/jama.2023.14443.
    PubMed    
    
    
    
43. ODOUARD IC, Socal MP, Anderson GF
    Role of Registries in Medicare Coverage of New Alzheimer Disease Drugs.
    JAMA. 2023 Sep 27. doi: 10.1001/jama.2023.17131.
    PubMed    
    
    
    
44. RUBIN R
    Consumers Can Now Buy a Blood Test to Evaluate Their Alzheimer Disease Risk, but Should They?
    JAMA. 2023 Sep 13. doi: 10.1001/jama.2023.17685.
    PubMed    
    
    
    August 2023
45. HARRIS E
    Study: Identifying Lewy Body Disease Before Symptoms.
    JAMA. 2023;330:686.
    PubMed    
    
    
    July 2023
46. HARRIS E
    MIND Diet No Better Than Control for Adults at Risk of Dementia.
    JAMA. 2023 Jul 26. doi: 10.1001/jama.2023.13134.
    PubMed    
    
    
    
47. HARRIS E
    Alzheimer Drug Lecanemab Gains Traditional FDA Approval.
    JAMA. 2023 Jul 19. doi: 10.1001/jama.2023.12548.
    PubMed    
    
    
    
48. SIMS JR, Zimmer JA, Evans CD, Lu M, et al
    Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
    JAMA. 2023 Jul 17:e2313239. doi: 10.1001/jama.2023.13239.
    PubMed     Abstract available
    
    
    
49. ROSENTHAL MB
    Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11702.
    PubMed    
    
    
    
50. MANLY JJ, Deters KD
    Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed?
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11704.
    PubMed    
    
    
    
51. RABINOVICI GD, La Joie R
    Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11703.
    PubMed    
    
    
    
52. WIDERA EW, Brangman SA, Chin NA
    Ushering in a New Era of Alzheimer Disease Therapy.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11701.
    PubMed    
    
    
    
53. HARRIS E
    More Lean Muscle Might Reduce Alzheimer Disease Risk.
    JAMA. 2023 Jul 12. doi: 10.1001/jama.2023.12544.
    PubMed    
    
    
    June 2023
54. HARRIS E
    CMS Will Cover Alzheimer Drugs With Traditional FDA Approval.
    JAMA. 2023 Jun 14. doi: 10.1001/jama.2023.10400.
    PubMed    
    
    
    
55. HARRIS E
    Brain Cell Biomarker for Preclinical Alzheimer Disease Identified.
    JAMA. 2023 Jun 7. doi: 10.1001/jama.2023.9928.
    PubMed    
    
    
    May 2023
56. HARRIS E
    FDA Greenlights First Drug for Agitation Related to Alzheimer Disease.
    JAMA. 2023 May 24. doi: 10.1001/jama.2023.9153.
    PubMed    
    
    
    
57. MARCUS R
    New Alzheimer Disease Drugs, Long COVID and the Central Nervous System, and a Nasal Spray for Migraines-Highlights From the 2023 American Academy of Neurology Conference.
    JAMA. 2023 May 10. doi: 10.1001/jama.2023.4389.
    PubMed    
    
    
    March 2023
58. HARRIS E
    Blood Biomarker Helps Distinguish Vascular Dementia.
    JAMA. 2023;329:969.
    PubMed    
    
    
    February 2023
59. HARRIS E
    Healthful Lifestyle May Slow Memory Loss, Even for APOE Gene Carriers.
    JAMA. 2023;329:622.
    PubMed    
    
    
    October 2021
60. EMANUEL EJ
    A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.
    JAMA. 2021;326:1367-1368.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum